Advanced

The costs of treating glaucoma with combinations of topical drugs in Spain

Neymark, N; Buchholz, P; Honrubia, F and Kobelt, Gisela LU (2008) In European Journal of Ophthalmology 18(1). p.52-59
Abstract
PURPOSE. This study describes the treatment in ordinary clinical practice in Spain of patients with glaucoma with a two-drug combination therapy. The authors present the treatment outcome as end-of-period intraocular pressure (IOP) and the calculated direct medical costs over a 2-year period. METHODS. Data were extracted retrospectively from patient charts recording the use of all medical resources related to glaucoma. Costs were estimated using unit costs from public sources ( 2005). Descriptive cost analysis according to combination treatment at baseline was performed. RESULTS. The study included 216 patients from 21 centers. Around half of the patients were started on a beta-blocker/prostaglandin analogue combination, while the rest... (More)
PURPOSE. This study describes the treatment in ordinary clinical practice in Spain of patients with glaucoma with a two-drug combination therapy. The authors present the treatment outcome as end-of-period intraocular pressure (IOP) and the calculated direct medical costs over a 2-year period. METHODS. Data were extracted retrospectively from patient charts recording the use of all medical resources related to glaucoma. Costs were estimated using unit costs from public sources ( 2005). Descriptive cost analysis according to combination treatment at baseline was performed. RESULTS. The study included 216 patients from 21 centers. Around half of the patients were started on a beta-blocker/prostaglandin analogue combination, while the rest received various other combinations containing either an alpha 2-agonist or a carbonic anhydrase inhibitor. Across the seven groups considered, there was a statistically significant difference in the costs of the least and the two most costly groups, while the confidence intervals were overlapping in all other pairwise comparisons. The least costly drug combination was brimonidine/timolol. Assessing IOP at the end of follow-up, all the groups were equally effective ( overlapping confidence intervals). In a multivariate regression analysis, the drug combination did not have an independent, significant impact on total direct medical costs, drug costs, or end-of-period IOP. Significant determinants of these variables were surgical interventions and one or more changes of drug combination during the follow-up. CONCLUSIONS. Costs are determined by the response to treatment. Inadequate response triggers treatment changes and sometimes eventually surgical interventions, thereby increasing costs significantly. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Spanish costs, glaucoma treatment, combination therapy, cost analysis
in
European Journal of Ophthalmology
volume
18
issue
1
pages
52 - 59
publisher
Wichtig Editore
external identifiers
  • pmid:18203085
  • wos:000253556900009
  • scopus:41149174879
ISSN
1120-6721
language
English
LU publication?
yes
id
fc7b9a7f-5f29-443f-820d-1a9e256290b8 (old id 1193842)
date added to LUP
2008-09-10 09:33:48
date last changed
2017-08-06 03:43:12
@article{fc7b9a7f-5f29-443f-820d-1a9e256290b8,
  abstract     = {PURPOSE. This study describes the treatment in ordinary clinical practice in Spain of patients with glaucoma with a two-drug combination therapy. The authors present the treatment outcome as end-of-period intraocular pressure (IOP) and the calculated direct medical costs over a 2-year period. METHODS. Data were extracted retrospectively from patient charts recording the use of all medical resources related to glaucoma. Costs were estimated using unit costs from public sources ( 2005). Descriptive cost analysis according to combination treatment at baseline was performed. RESULTS. The study included 216 patients from 21 centers. Around half of the patients were started on a beta-blocker/prostaglandin analogue combination, while the rest received various other combinations containing either an alpha 2-agonist or a carbonic anhydrase inhibitor. Across the seven groups considered, there was a statistically significant difference in the costs of the least and the two most costly groups, while the confidence intervals were overlapping in all other pairwise comparisons. The least costly drug combination was brimonidine/timolol. Assessing IOP at the end of follow-up, all the groups were equally effective ( overlapping confidence intervals). In a multivariate regression analysis, the drug combination did not have an independent, significant impact on total direct medical costs, drug costs, or end-of-period IOP. Significant determinants of these variables were surgical interventions and one or more changes of drug combination during the follow-up. CONCLUSIONS. Costs are determined by the response to treatment. Inadequate response triggers treatment changes and sometimes eventually surgical interventions, thereby increasing costs significantly.},
  author       = {Neymark, N and Buchholz, P and Honrubia, F and Kobelt, Gisela},
  issn         = {1120-6721},
  keyword      = {Spanish costs,glaucoma treatment,combination therapy,cost analysis},
  language     = {eng},
  number       = {1},
  pages        = {52--59},
  publisher    = {Wichtig Editore},
  series       = {European Journal of Ophthalmology},
  title        = {The costs of treating glaucoma with combinations of topical drugs in Spain},
  volume       = {18},
  year         = {2008},
}